- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Icosapent Ethyl Cost-Effective Treatment Option for high-risk patients with hypertriglyceridemia
The Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT) demonstrated the efficacy of icosapent ethyl (IPE) for high-risk patients with hypertriglyceridemia and known cardiovascular disease or diabetes and at least 1 other risk factor who were treated with statins.
A recent study suggests that for high-risk patients with hypertriglyceridemia despite statin treatment, icosapent ethyl may be cost-effective at commonly accepted willingness-to-pay thresholds. The study findings were published in the JAMA Network Open on February 14, 2022.
Although REDUCE-IT demonstrated the efficacy and safety of IPE in reducing cardiovascular events among high-risk patients, some say IPE is priced too high and that patients aren't always able to receive it. Therefore, Dr William S. Weintraub and his team conducted a study to estimate the cost-effectiveness of IPE compared with standard care for high-risk patients with hypertriglyceridemia despite statin treatment.
The researchers conducted an in-trial cost-effectiveness analysis using patient-level study data from REDUCE-IT. They further performed a lifetime analysis using a microsimulation model and data from published literature. The researchers included a total of 8179 patients with hypertriglyceridemia despite stable statin therapy and randomly assigned them to IPE4 g/d (n= 4089) or placebo (n=4090) and followed them for a median of 4.9 years.
The cost of IPE was $4.16 per day after rebates using SSR Health net cost (SSR cost) and $9.28 per day with wholesale acquisition cost (WAC). The major outcome assessed was incremental quality-adjusted life-years (QALYs), total direct health care costs (2019 US dollars), and cost-effectiveness.
Key findings of the study:
- Upon analysis, the researchers found that the treatment with IPE yielded more QALYs than standard care both in the trial (3.34 vs 3.27; mean difference, 0.07) and over a lifetime projection (10.59 vs 10.35; mean difference, 0.24).
- However, upon In-trial, they noted that the total health care costs were higher with IPE using either SSR cost ($18 786) or WAC ($24 544) than with standard care ($17 273; mean difference from SSR cost, $1513; mean difference from WAC, $7271).
- They found that IPE cost $22 311 per QALY gained using SSR cost and $107 218 per QALY gained using WAC.
- Upon lifetime analysis, they found that IPE was projected to be cost-saving when using SSR cost ($195 276) compared with standard care ($197 064; mean difference, –$1788). However, they noted higher costs when using WAC ($202 830) compared with standard care (mean difference, $5766).
- Compared with standard care, they found that IPE had a 58.4% lifetime probability of costing less and being more effective when using SSR cost and an 89.4% probability of costing less than $50 000 per QALY gained when using SSR cost and a 72.5% probability of costing less than $50 000 per QALY gained when using WAC.
The authors concluded, "In this patient-level cost-effectiveness analysis of REDUCE-IT, IPE was projected to be cost-effective compared with standard care, both during the trial and over a lifetime, with an ICER below commonly accepted WTP thresholds. The findings suggest that treatment with IPE may be cost-effective among patients with high cardiovascular risk whose triglyceride levels remain high despite statin therapy."
In an accompanying editorial Dr Dariush Mozaffarian wrote, "Continued development of cost-effective medical treatments such as IPE is important. At the same time, nations will not achieve better health, more health equity, or lower health care spending until they equally emphasize and invest in public health and prevention policy to reduce lifestyle-related chronic diseases."
For further information:
DOI:10.1001/jamanetworkopen.2021.48172
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751